UNCY LAWSUIT ALERT: Levi & Korsinsky Notifies Unicycive Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Core Points - A class action securities lawsuit has been filed against Unicycive Therapeutics, Inc. for alleged securities fraud affecting investors between March 29, 2024, and June 27, 2025 [1][2] - The lawsuit claims that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements and the regulatory prospects of its oxylanthanum carbonate new drug application [2] - Investors who suffered losses during the specified period have until October 14, 2025, to request to be appointed as lead plaintiff, with no out-of-pocket costs to participate [3] Company Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]